SWKHL SWK Holdings Corporation 9.00% Senior Notes due 2027
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel floor · 3-year channel rising
Price is on the lower line, where it has held before.
- 3-year channel
- US$26.04 – US$39.41 · rising, +10% a year
- Price in channel
- −4.2% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$39.41
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 8:59 AM ET (2 h ago)
- Daily close
- Upper trend line (3 years)
- Lower trend line (3 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call: there is not enough recent history to price an entry Levels below are for reference only.
Buy now
US$25.48
last close · 4 Sept 2026
Our target
US$40.63
by 30 Jan 2027
Projected move
59.5%
gross, before costs
Last close is our buy.
- Upper line touches
- 4
- Lower line touches
- 3
- Fit confidence
- 95%
- Fitted
- 1 Nov 2026
Company information
About SWK Holdings Corporation 9.00% Senior Notes due 2027
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
- Sector
- Financial Services
- Industry
- Financial - Credit Services
- CEO
- Jody. D Staggs
- Employees
- 24
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$192.40M
- Enterprise value
- —
- Beta
- 0.06
- Avg volume
- 3.69K
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 24.34-25.92
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.